ST-ME01, for the treatment of hypothyroidism, is a unique combination of levothyroxine and liothyronine (T4 and T3) unlike anything on the market. Designed to mimic a healthy thyroid’s circadian release of these hormones. Our multi-particulate drug release technology enables production of ST-ME01 in dose proportional formulations that can be tailored to a patient’s individual needs.
ST-RHU02 is a proprietary formulation for a once daily treatment of dry mouth and eyes associated with Sjögren’s syndrome.
Our technologies utilize ion exchange resin to form a multi-particulate drug-resin complex and provides an enhanced drug release profile to increase efficacy and lessen side effects.
Clinical trials will occur after pre-IND meetings with the FDA and are expected to commence within the next two years. Updates will be posted as developments unfold.